Text Size

Topical cis-urocanic acid prevents ocular surface irritation in both IgE -independent and -mediated rat model

Jauhonen H.-M., Laihia J., Oksala O., Viiri J., Sironen R., Alajuuma P., Kaarniranta K., Leino L.


  • 2017
  • Graefe's Archive for Clinical and Experimental Ophthalmology
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Preclinical development

  • Affiliations

    Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland; Institute of Clinical Medicine, Department of Ophthalmology, University of Eastern Finland, Kuopio, Finland; Department of Ophthalmology, University of Eastern Finland and Kuopio University Hospital, Finland, P.O. Box 1627, Kuopio, FIN-70211, Finland; BioCis Pharma Ltd, Turku, Finland; Santen Oy, Tampere, Finland; Institute of Clinical Medicine, Department of Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland; Department of Pathology, Kuopio University Hospital, Kuopio, Finland

Related Publications

Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.


Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.


Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis

Ogura N., Fujisawa K., Kato M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022